AusPAR: Eftrenonacog alfa

Australian Public Assessment Report

AusPAR

AusPAR: Eftrenonacog alfa [PDF, 592.9 KB]

AusPAR: Eftrenonacog alfa [Word, 1.05 MB]

Attachment: Product Information: Eftrenonacog alfa [PDF, 365.44 KB]

Attachment: Product Information: Eftrenonacog alfa [Word, 375.69 KB]

Attachment: Extract from the Clinical Evaluation Report: Eftrenonacog alfa [PDF, 1.38 MB]

Attachment: Extract from the Clinical Evaluation Report: Eftrenonacog alfa [Word, 3.03 MB]

Device/Product Name

Alprolix

Active ingredients

Eftrenonacog alfa

AusPAR Date

3 November 2014

Published

19 November 2014

Submission Number

PM-2013-00745-1-4

Submission Type

New biological entity

Decision

Approved

This webpage on the TGA website was printed on 12 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/resources/auspar/auspar-eftrenonacog-alfa

Sub menu

AusPAR: Eftrenonacog alfa

Help us improve the Therapeutic Goods Administration site